APO Research
Talk to an analyst

APO RESEARCH · REPORT

Veterinary Lyme Disease Vaccines

Veterinary Lyme disease vaccines are companion-animal biologics designed to reduce the probability and magnitude of infection with Borreliella (Borrelia) burgdorferi sensu lato after exposure to competent Ixodes ticks. The commercial and clinical category is functionally canine; a limited feline line exists in parts of Europe, and there are no licensed equine or food-animal products. Use is risk-based rather than core and is paired with acaricides and environmental tick management. The etiologic agents are host-adapted spirochetes maintained in an enzootic cycle linking small mammals and certain birds with hard ticks. Larval and nymphal Ixodes acquire organisms during a blood meal, retain them transstadially, and transmit during subsequent feeding. Within unfed ticks, spirochetes occupy a vector-adapted state; attachment and feeding trigger a transcriptional switch toward mammalian-phase biology, down-regulating vector-phase genes and up-regulating mammalian-phase genes as organisms exit the midgut for the salivary glands. Geographically, veterinary and human hotspots mirror vector ranges: I. scapularis in the northeastern and upper midwestern United States with a coastal Pacific belt under I. pacificus; I. ricinus across temperate Europe; and I. persulcatus across northern Eurasia. North American canine disease is dominated by B. burgdorferi sensu stricto, whereas B. garinii and B. afzelii contribute materially in Europe and the UK; stable natural foci also occur across parts of northeastern Asia.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Veterinary Lyme disease vaccines are companion-animal biologics designed to reduce the probability and magnitude of infection with Borreliella (Borrelia) burgdorferi sensu lato after exposure to competent Ixodes ticks. The commercial and clinical category is functionally canine; a limited feline line exists in parts of Europe, and there are no licensed equine or food-animal products. Use is risk-based rather than core and is paired with acaricides and environmental tick management. The etiologic agents are host-adapted spirochetes maintained in an enzootic cycle linking small mammals and certain birds with hard ticks. Larval and nymphal Ixodes acquire organisms during a blood meal, retain them transstadially, and transmit during subsequent feeding. Within unfed ticks, spirochetes occupy a vector-adapted state; attachment and feeding trigger a transcriptional switch toward mammalian-phase biology, down-regulating vector-phase genes and up-regulating mammalian-phase genes as organisms exit the midgut for the salivary glands. Geographically, veterinary and human hotspots mirror vector ranges: I. scapularis in the northeastern and upper midwestern United States with a coastal Pacific belt under I. pacificus; I. ricinus across temperate Europe; and I. persulcatus across northern Eurasia. North American canine disease is dominated by B. burgdorferi sensu stricto, whereas B. garinii and B. afzelii contribute materially in Europe and the UK; stable natural foci also occur across parts of northeastern Asia.

Two vaccine platforms encompass licensed products and map onto distinct biological bottlenecks. Bacterins are inactivated whole-cell preparations that present broad antigenic repertoires; in commerce they are typically bivalent by strain in North America and trivalent in Europe to align with regional sensu lato diversity. Recombinant protein subunits are defined-composition formulations built around outer-surface lipoproteins with established protective correlates. One branch uses lipidated outer surface protein A (OspA) as a single antigen; the other pairs OspA with an engineered OspC chimeric epitope protein (“chimeritope”) that concatenates linear epitopes from multiple OspC types to extend breadth. Mechanistically, anti-OspA antibodies act mainly within the feeding tick midgut, binding OspA on vector-phase organisms and impeding survival and transmission, whereas anti-OspC antibodies act in the early mammalian window at the bite site and draining tissues, promoting neutralization and opsonophagocytic clearance before hematogenous dissemination. The responses are temporally complementary and address distinct transmission bottlenecks.

Antigen-level detail underpins both design and diagnostics. OspA is a lipidated outer-membrane lipoprotein abundantly expressed by unfed tick-phase organisms; protective B-cell epitopes cluster toward the C-terminal domain, the locus of canonical neutralizing monoclonals, and OspA is down-regulated during feeding and host entry, which explains its principal value at the vector interface and its pairing with mammalian-phase antigens in some subunits. OspC is a smaller, dimeric lipoprotein whose transcription is strongly induced during tick feeding and the first days of mammalian infection; it contributes to early tissue invasion and complement interactions and is a dominant target of early humoral responses. OspC is highly polymorphic and partitioned into dozens of phylogenetic types maintained by recombination and frequency-dependent selection; antibody responses are largely type-specific and cross-protection is limited. Chimeritope designs address this constraint by assembling immunodominant linear segments—classically from the variable L5 and H5 regions—drawn from representative OspC types into a single recombinant antigen capable of broad binding across OspC diversity. In genomic context, OspA is encoded on lp54, OspC on cp26, and the vls cassette system on lp28-1 underpins antigenic variation during persistence; this plasmid architecture explains phase-specific expression and immune evasion. Serology follows from these rules: antibodies to the VlsE-derived C6 peptide track natural infection and are not induced by OspA-only vaccination, whereas bacterins and OspC-containing subunits broaden antibody profiles and require assay selection and clinical correlation to distinguish vaccine responses from infection.

Historically, the category progressed from whole-cell to defined-antigen formulations. Early licensed canine products in the 1990s were formalin-inactivated cell-lysate bacterins (e.g., LymeVax and Galaxy Lyme). The next phase introduced recombinant OspA subunits to avoid nonessential antigens and focus on vector-phase blockade. From the mid-2010s, OspA plus OspC chimeritope formulations appeared, targeting both the tick midgut and the early mammalian phase while addressing OspC’s strong polymorphism. This trajectory reflects a shift from breadth via whole-cell antigen overload to breadth-with-specificity via defined antigens, with corresponding gains in compositional clarity and mechanistic alignment to transmission biology.

The global burden aligns with vector ecology and surveillance intensity. In the United States, highest veterinary and human risk occurs from the mid-Atlantic through New England and the upper Midwest, with additional foci on the Pacific coast; in Canada, risk concentrates in southern Ontario, Québec, the Maritimes, and expanding prairie and coastal belts. In Europe, risk spans the UK and Ireland, the Benelux and Alpine corridors, Germany and Poland, the Baltics and Scandinavia, and northern Mediterranean foothills where I. ricinus is established. Across northern Eurasia, I. persulcatus supports foci from northeastern Europe through western Russia into Siberia and parts of the Far East. Outside North America and Europe many jurisdictions do not license canine Lyme vaccines and rely on acaricides and exposure management.

Current products in commerce resolve to a short, well-defined list whose differences are meaningful at the level of antigen strategy, breadth, and evidentiary posture rather than dose logistics. VANGUARD® crLyme is an OspA plus OspC chimeritope subunit; the OspC component presents a panel of linear epitopes drawn from diverse OspC types, aiming to maintain binding breadth across local OspC ecologies while pairing vector-phase interception with early mammalian-phase neutralization. This defined-composition approach yields strong titers to both components, challenge-model protection across infection and histopathology endpoints, and an extended duration-of-immunity label in its home market; trade-offs include broader serologic footprints that can complicate interpretation on certain assays and a dependence on epitope selection relative to regional OspC phylogeny. RECOMBITEK® Lyme (rLyme) is a non-adjuvanted, lipidated OspA subunit that emphasizes a tight antigen profile and a vector-interface mechanism; benefits include minimal extraneous proteins and preserved interpretability of C6-based diagnostics, while constraints center on the absence of an explicit OspC component, making timely transmission interception and booster maintenance central to performance. Nobivac® Lyme is a bivalent bacterin built around two B. burgdorferi sensu stricto strains selected to emphasize OspA and OspC expression characteristics; it delivers broad borreliacidal responses with long field experience and a 12-month duration label in its home market, balanced against the inherent complexity of whole-cell formulations and limited public standardization of OspC expression in production cultures. Duramune® Lyme and Ultra Duramune® Lyme—and their successor branding TruCan™ Lyme and TruCan™ Ultra Lyme—are bivalent bacterins positioned for breadth and for integration into combination presentations with Leptospira or broader canine cores; strengths include robust whole-cell immunogenic breadth and portfolio flexibility, while constraints mirror the bacterin class: extraneous-antigen overhead, culture-stage expression variability, and the fact that reduced fill volume by itself does not evidence superior protection. In Europe and the UK, Borrelym 3 and Merilym 3 are trivalent bacterins that include B. afzelii, B. garinii, and B. burgdorferi sensu stricto to match regional sensu lato diversity; they are well aligned to I. ricinus regions but, as whole-cell products, share the class’s compositional constraints and have limited public species-specific protection data versus each included sensu lato species. Within the same manufacturer’s portfolio, Biocan B is a canine bacterin used where national registrations permit, and Biofel B is a niche feline bacterin available in limited jurisdictions; both follow the bacterin paradigm with corresponding advantages in breadth and constraints in specificity and transparency.

Taken together, veterinary Lyme disease vaccines are best understood as a small, mechanism-anchored category defined by two platforms, two principal antigens with distinct temporal loci of action, and a finite set of market models whose antigen strategies map directly onto transmission biology. Bacterins trade compositional complexity for breadth; OspA subunits trade breadth for precision at the vector interface; OspA plus OspC chimeritopes aim to recapture breadth with defined antigens by spanning vector and early mammalian phases. Regional epidemiology and OspC phylogeny shape optimal fit, diagnostics must be interpreted with platform awareness, and program value is maximized when vaccination is integrated with acaricides and exposure management in dogs genuinely at risk.

Selected research

Market Analysis & Forecast

Global Veterinary Lyme Disease Vaccines Market Analysis and Forecast 2026-2032

21 December 2025190 pages

Choose your research edition.

Industry ResearchVeterinary Lyme Disease Vaccines Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Veterinary Lyme Disease Vaccines Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Veterinary Lyme Disease Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Veterinary Lyme Disease Vaccines Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Veterinary Lyme Disease Vaccines Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Veterinary Lyme disease vaccines are companion-animal biologics designed to reduce the probability and magnitude of infection with Borreliella (Borrelia) burgdorferi sensu lato after exposure to competent Ixodes ticks. The commercial and clinical category is functionally canine; a limited feline line exists in parts of Europe, and there are no licensed equine or food-animal products. Use is risk-based rather than core and is paired with acaricides and environmental tick management. The etiologic agents are host-adapted spirochetes maintained in an enzootic cycle linking small mammals and certain birds with hard ticks. Larval and nymphal Ixodes acquire organisms during a blood meal, retain them transstadially, and transmit during subsequent feeding. Within unfed ticks, spirochetes occupy a vector-adapted state; attachment and feeding trigger a transcriptional switch toward mammalian-phase biology, down-regulating vector-phase genes and up-regulating mammalian-phase genes as organisms exit the midgut for the salivary glands. Geographically, veterinary and human hotspots mirror vector ranges: I. scapularis in the northeastern and upper midwestern United States with a coastal Pacific belt under I. pacificus; I. ricinus across temperate Europe; and I. persulcatus across northern Eurasia. North American canine disease is dominated by B. burgdorferi sensu stricto, whereas B. garinii and B. afzelii contribute materially in Europe and the UK; stable natural foci also occur across parts of northeastern Asia.

Two vaccine platforms encompass licensed products and map onto distinct biological bottlenecks. Bacterins are inactivated whole-cell preparations that present broad antigenic repertoires; in commerce they are typically bivalent by strain in North America and trivalent in Europe to align with regional sensu lato diversity. Recombinant protein subunits are defined-composition formulations built around outer-surface lipoproteins with established protective correlates. One branch uses lipidated outer surface protein A (OspA) as a single antigen; the other pairs OspA with an engineered OspC chimeric epitope protein (“chimeritope”) that concatenates linear epitopes from multiple OspC types to extend breadth. Mechanistically, anti-OspA antibodies act mainly within the feeding tick midgut, binding OspA on vector-phase organisms and impeding survival and transmission, whereas anti-OspC antibodies act in the early mammalian window at the bite site and draining tissues, promoting neutralization and opsonophagocytic clearance before hematogenous dissemination. The responses are temporally complementary and address distinct transmission bottlenecks.

Antigen-level detail underpins both design and diagnostics. OspA is a lipidated outer-membrane lipoprotein abundantly expressed by unfed tick-phase organisms; protective B-cell epitopes cluster toward the C-terminal domain, the locus of canonical neutralizing monoclonals, and OspA is down-regulated during feeding and host entry, which explains its principal value at the vector interface and its pairing with mammalian-phase antigens in some subunits. OspC is a smaller, dimeric lipoprotein whose transcription is strongly induced during tick feeding and the first days of mammalian infection; it contributes to early tissue invasion and complement interactions and is a dominant target of early humoral responses. OspC is highly polymorphic and partitioned into dozens of phylogenetic types maintained by recombination and frequency-dependent selection; antibody responses are largely type-specific and cross-protection is limited. Chimeritope designs address this constraint by assembling immunodominant linear segments—classically from the variable L5 and H5 regions—drawn from representative OspC types into a single recombinant antigen capable of broad binding across OspC diversity. In genomic context, OspA is encoded on lp54, OspC on cp26, and the vls cassette system on lp28-1 underpins antigenic variation during persistence; this plasmid architecture explains phase-specific expression and immune evasion. Serology follows from these rules: antibodies to the VlsE-derived C6 peptide track natural infection and are not induced by OspA-only vaccination, whereas bacterins and OspC-containing subunits broaden antibody profiles and require assay selection and clinical correlation to distinguish vaccine responses from infection.

Read the full market overview

Historically, the category progressed from whole-cell to defined-antigen formulations. Early licensed canine products in the 1990s were formalin-inactivated cell-lysate bacterins (e.g., LymeVax and Galaxy Lyme). The next phase introduced recombinant OspA subunits to avoid nonessential antigens and focus on vector-phase blockade. From the mid-2010s, OspA plus OspC chimeritope formulations appeared, targeting both the tick midgut and the early mammalian phase while addressing OspC’s strong polymorphism. This trajectory reflects a shift from breadth via whole-cell antigen overload to breadth-with-specificity via defined antigens, with corresponding gains in compositional clarity and mechanistic alignment to transmission biology.

The global burden aligns with vector ecology and surveillance intensity. In the United States, highest veterinary and human risk occurs from the mid-Atlantic through New England and the upper Midwest, with additional foci on the Pacific coast; in Canada, risk concentrates in southern Ontario, Québec, the Maritimes, and expanding prairie and coastal belts. In Europe, risk spans the UK and Ireland, the Benelux and Alpine corridors, Germany and Poland, the Baltics and Scandinavia, and northern Mediterranean foothills where I. ricinus is established. Across northern Eurasia, I. persulcatus supports foci from northeastern Europe through western Russia into Siberia and parts of the Far East. Outside North America and Europe many jurisdictions do not license canine Lyme vaccines and rely on acaricides and exposure management.

Current products in commerce resolve to a short, well-defined list whose differences are meaningful at the level of antigen strategy, breadth, and evidentiary posture rather than dose logistics. VANGUARD® crLyme is an OspA plus OspC chimeritope subunit; the OspC component presents a panel of linear epitopes drawn from diverse OspC types, aiming to maintain binding breadth across local OspC ecologies while pairing vector-phase interception with early mammalian-phase neutralization. This defined-composition approach yields strong titers to both components, challenge-model protection across infection and histopathology endpoints, and an extended duration-of-immunity label in its home market; trade-offs include broader serologic footprints that can complicate interpretation on certain assays and a dependence on epitope selection relative to regional OspC phylogeny. RECOMBITEK® Lyme (rLyme) is a non-adjuvanted, lipidated OspA subunit that emphasizes a tight antigen profile and a vector-interface mechanism; benefits include minimal extraneous proteins and preserved interpretability of C6-based diagnostics, while constraints center on the absence of an explicit OspC component, making timely transmission interception and booster maintenance central to performance. Nobivac® Lyme is a bivalent bacterin built around two B. burgdorferi sensu stricto strains selected to emphasize OspA and OspC expression characteristics; it delivers broad borreliacidal responses with long field experience and a 12-month duration label in its home market, balanced against the inherent complexity of whole-cell formulations and limited public standardization of OspC expression in production cultures. Duramune® Lyme and Ultra Duramune® Lyme—and their successor branding TruCan™ Lyme and TruCan™ Ultra Lyme—are bivalent bacterins positioned for breadth and for integration into combination presentations with Leptospira or broader canine cores; strengths include robust whole-cell immunogenic breadth and portfolio flexibility, while constraints mirror the bacterin class: extraneous-antigen overhead, culture-stage expression variability, and the fact that reduced fill volume by itself does not evidence superior protection. In Europe and the UK, Borrelym 3 and Merilym 3 are trivalent bacterins that include B. afzelii, B. garinii, and B. burgdorferi sensu stricto to match regional sensu lato diversity; they are well aligned to I. ricinus regions but, as whole-cell products, share the class’s compositional constraints and have limited public species-specific protection data versus each included sensu lato species. Within the same manufacturer’s portfolio, Biocan B is a canine bacterin used where national registrations permit, and Biofel B is a niche feline bacterin available in limited jurisdictions; both follow the bacterin paradigm with corresponding advantages in breadth and constraints in specificity and transparency.

Taken together, veterinary Lyme disease vaccines are best understood as a small, mechanism-anchored category defined by two platforms, two principal antigens with distinct temporal loci of action, and a finite set of market models whose antigen strategies map directly onto transmission biology. Bacterins trade compositional complexity for breadth; OspA subunits trade breadth for precision at the vector interface; OspA plus OspC chimeritopes aim to recapture breadth with defined antigens by spanning vector and early mammalian phases. Regional epidemiology and OspC phylogeny shape optimal fit, diagnostics must be interpreted with platform awareness, and program value is maximized when vaccination is integrated with acaricides and exposure management in dogs genuinely at risk.

The global Veterinary Lyme Disease Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Veterinary Lyme Disease Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Veterinary Lyme Disease Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Asia-Pacific market for Veterinary Lyme Disease Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Veterinary Lyme Disease Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Veterinary Lyme Disease Vaccines include Zoetis, Boehringer Ingelheim, Elanco, Merck Animal Health and Bioveta, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Veterinary Lyme Disease Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Veterinary Lyme Disease Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Veterinary Lyme Disease Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Veterinary Lyme Disease Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Veterinary Lyme Disease Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Veterinary Lyme Disease Vaccines sales, projected growth trends, production technology, application and end-user industry.

Veterinary Lyme Disease Vaccines Segment by Company

Zoetis

Boehringer Ingelheim

Elanco

Merck Animal Health

Bioveta

Veterinary Lyme Disease Vaccines Segment by Type

Recombinant Subunit Vaccines

Bacterin Vaccines

Veterinary Lyme Disease Vaccines Segment by Application

Canine

Feline

Veterinary Lyme Disease Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Veterinary Lyme Disease Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Veterinary Lyme Disease Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Veterinary Lyme Disease Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Veterinary Lyme Disease Vaccines in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Veterinary Lyme Disease Vaccines manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Veterinary Lyme Disease Vaccines sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Veterinary Lyme Disease Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Recombinant Subunit Vaccines Major Manufacturers Table 3. Bacterin Vaccines Major Manufacturers Table 4. Global Veterinary Lyme Disease Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Canine Major Manufacturers Table 6. Feline Major Manufacturers Table 7. Veterinary Lyme Disease Vaccines Industry Trends Table 8. Veterinary Lyme Disease Vaccines Industry Drivers Table 9. Veterinary Lyme Disease Vaccines Industry Opportunities and Challenges Table 10. Veterinary Lyme Disease Vaccines Industry Restraints Table 11. Global Veterinary Lyme Disease Vaccines Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 12. Global Veterinary Lyme Disease Vaccines Revenue by Region (2021-2026) & (US$ Million) Table 13. Global Veterinary Lyme Disease Vaccines Revenue by Region (2027-2032) & (US$ Million) Table 14. Global Veterinary Lyme Disease Vaccines Revenue Market Share by Region (2021-2026) Table 15. Global Veterinary Lyme Disease Vaccines Revenue Market Share by Region (2027-2032) Table 16. Global Veterinary Lyme Disease Vaccines Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k doses) Table 17. Global Veterinary Lyme Disease Vaccines Sales by Region (2021-2026) & (k doses) Table 18. Global Veterinary Lyme Disease Vaccines Sales by Region (2027-2032) & (k doses) Table 19. Global Veterinary Lyme Disease Vaccines Sales Market Share by Region (2021-2026) Table 20. Global Veterinary Lyme Disease Vaccines Sales Market Share by Region (2027-2032) Table 21. Global Veterinary Lyme Disease Vaccines Revenue by Manufacturers (US$ Million) & (2021-2026) Table 22. Global Veterinary Lyme Disease Vaccines Revenue Market Share by Manufacturers (2021-2026) Table 23. Global Veterinary Lyme Disease Vaccines Sales by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Veterinary Lyme Disease Vaccines Sales Market Share by Manufacturers (2021-2026) Table 25. Global Veterinary Lyme Disease Vaccines Sales Price (USD/dose) of Manufacturers (2021-2026) Table 26. Global Veterinary Lyme Disease Vaccines Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 27. Global Veterinary Lyme Disease Vaccines Key Manufacturers Manufacturing Sites & Headquarters Table 28. Global Veterinary Lyme Disease Vaccines Manufacturers, Product Type & Application Table 29. Global Veterinary Lyme Disease Vaccines Manufacturers' Establishment Date Table 30. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 31. Global Veterinary Lyme Disease Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 32. Global Veterinary Lyme Disease Vaccines Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Veterinary Lyme Disease Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 34. Global Veterinary Lyme Disease Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 35. Global Veterinary Lyme Disease Vaccines Revenue Market Share by Type (2021-2026) Table 36. Global Veterinary Lyme Disease Vaccines Revenue Market Share by Type (2027-2032) Table 37. Global Veterinary Lyme Disease Vaccines Sales by Type 2021 VS 2025 VS 2032 (k doses) Table 38. Global Veterinary Lyme Disease Vaccines Sales by Type (2021-2026) & (k doses) Table 39. Global Veterinary Lyme Disease Vaccines Sales by Type (2027-2032) & (k doses) Table 40. Global Veterinary Lyme Disease Vaccines Sales Market Share by Type (2021-2026) Table 41. Global Veterinary Lyme Disease Vaccines Sales Market Share by Type (2027-2032) Table 42. Global Veterinary Lyme Disease Vaccines Price by Type (2021-2026) & (USD/dose) Table 43. Global Veterinary Lyme Disease Vaccines Price by Type (2027-2032) & (USD/dose) Table 44. Global Veterinary Lyme Disease Vaccines Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Veterinary Lyme Disease Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 46. Global Veterinary Lyme Disease Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 47. Global Veterinary Lyme Disease Vaccines Revenue Market Share by Application (2021-2026) Table 48. Global Veterinary Lyme Disease Vaccines Revenue Market Share by Application (2027-2032) Table 49. Global Veterinary Lyme Disease Vaccines Sales by Application 2021 VS 2025 VS 2032 (k doses) Table 50. Global Veterinary Lyme Disease Vaccines Sales by Application (2021-2026) & (k doses) Table 51. Global Veterinary Lyme Disease Vaccines Sales by Application (2027-2032) & (k doses) Table 52. Global Veterinary Lyme Disease Vaccines Sales Market Share by Application (2021-2026) Table 53. Global Veterinary Lyme Disease Vaccines Sales Market Share by Application (2027-2032) Table 54. Global Veterinary Lyme Disease Vaccines Price by Application (2021-2026) & (USD/dose) Table 55. Global Veterinary Lyme Disease Vaccines Price by Application (2027-2032) & (USD/dose) Table 56. Zoetis Company Information Table 57. Zoetis Business Overview Table 58. Zoetis Veterinary Lyme Disease Vaccines Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 59. Zoetis Veterinary Lyme Disease Vaccines Product Portfolio Table 60. Zoetis Recent Development Table 61. Boehringer Ingelheim Company Information Table 62. Boehringer Ingelheim Business Overview Table 63. Boehringer Ingelheim Veterinary Lyme Disease Vaccines Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 64. Boehringer Ingelheim Veterinary Lyme Disease Vaccines Product Portfolio Table 65. Boehringer Ingelheim Recent Development Table 66. Elanco Company Information Table 67. Elanco Business Overview Table 68. Elanco Veterinary Lyme Disease Vaccines Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 69. Elanco Veterinary Lyme Disease Vaccines Product Portfolio Table 70. Elanco Recent Development Table 71. Merck Animal Health Company Information Table 72. Merck Animal Health Business Overview Table 73. Merck Animal Health Veterinary Lyme Disease Vaccines Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 74. Merck Animal Health Veterinary Lyme Disease Vaccines Product Portfolio Table 75. Merck Animal Health Recent Development Table 76. Bioveta Company Information Table 77. Bioveta Business Overview Table 78. Bioveta Veterinary Lyme Disease Vaccines Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 79. Bioveta Veterinary Lyme Disease Vaccines Product Portfolio Table 80. Bioveta Recent Development Table 81. North America Veterinary Lyme Disease Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 82. North America Veterinary Lyme Disease Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 83. North America Veterinary Lyme Disease Vaccines Sales by Type (2021-2026) & (k doses) Table 84. North America Veterinary Lyme Disease Vaccines Sales by Type (2027-2032) & (k doses) Table 85. North America Veterinary Lyme Disease Vaccines Sales Price by Type (2021-2026) & (USD/dose) Table 86. North America Veterinary Lyme Disease Vaccines Sales Price by Type (2027-2032) & (USD/dose) Table 87. North America Veterinary Lyme Disease Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 88. North America Veterinary Lyme Disease Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 89. North America Veterinary Lyme Disease Vaccines Sales by Application (2021-2026) & (k doses) Table 90. North America Veterinary Lyme Disease Vaccines Sales by Application (2027-2032) & (k doses) Table 91. North America Veterinary Lyme Disease Vaccines Sales Price by Application (2021-2026) & (USD/dose) Table 92. North America Veterinary Lyme Disease Vaccines Sales Price by Application (2027-2032) & (USD/dose) Table 93. North America Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 94. North America Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 95. North America Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 96. North America Veterinary Lyme Disease Vaccines Sales by Country (2021 VS 2025 VS 2032) & (k doses) Table 97. North America Veterinary Lyme Disease Vaccines Sales by Country (2021-2026) & (k doses) Table 98. North America Veterinary Lyme Disease Vaccines Sales by Country (2027-2032) & (k doses) Table 99. North America Veterinary Lyme Disease Vaccines Sales Price by Country (2021-2026) & (USD/dose) Table 100. North America Veterinary Lyme Disease Vaccines Sales Price by Country (2027-2032) & (USD/dose) Table 101. United States Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 102. Canada Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 103. Mexico Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 104. Europe Veterinary Lyme Disease Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 105. Europe Veterinary Lyme Disease Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 106. Europe Veterinary Lyme Disease Vaccines Sales by Type (2021-2026) & (k doses) Table 107. Europe Veterinary Lyme Disease Vaccines Sales by Type (2027-2032) & (k doses) Table 108. Europe Veterinary Lyme Disease Vaccines Sales Price by Type (2021-2026) & (USD/dose) Table 109. Europe Veterinary Lyme Disease Vaccines Sales Price by Type (2027-2032) & (USD/dose) Table 110. Europe Veterinary Lyme Disease Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 111. Europe Veterinary Lyme Disease Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 112. Europe Veterinary Lyme Disease Vaccines Sales by Application (2021-2026) & (k doses) Table 113. Europe Veterinary Lyme Disease Vaccines Sales by Application (2027-2032) & (k doses) Table 114. Europe Veterinary Lyme Disease Vaccines Sales Price by Application (2021-2026) & (USD/dose) Table 115. Europe Veterinary Lyme Disease Vaccines Sales Price by Application (2027-2032) & (USD/dose) Table 116. Europe Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. Europe Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 118. Europe Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 119. Europe Veterinary Lyme Disease Vaccines Sales by Country (2021 VS 2025 VS 2032) & (k doses) Table 120. Europe Veterinary Lyme Disease Vaccines Sales by Country (2021-2026) & (k doses) Table 121. Europe Veterinary Lyme Disease Vaccines Sales by Country (2027-2032) & (k doses) Table 122. Europe Veterinary Lyme Disease Vaccines Sales Price by Country (2021-2026) & (USD/dose) Table 123. Europe Veterinary Lyme Disease Vaccines Sales Price by Country (2027-2032) & (USD/dose) Table 124. Germany Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 125. France Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 126. U.K. Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 127. Italy Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 128. Russia Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 129. Spain Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 130. Netherlands Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 131. Switzerland Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 132. Sweden Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 133. Poland Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 134. China Veterinary Lyme Disease Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 135. China Veterinary Lyme Disease Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 136. China Veterinary Lyme Disease Vaccines Sales by Type (2021-2026) & (k doses) Table 137. China Veterinary Lyme Disease Vaccines Sales by Type (2027-2032) & (k doses) Table 138. China Veterinary Lyme Disease Vaccines Sales Price by Type (2021-2026) & (USD/dose) Table 139. China Veterinary Lyme Disease Vaccines Sales Price by Type (2027-2032) & (USD/dose) Table 140. China Veterinary Lyme Disease Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 141. China Veterinary Lyme Disease Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 142. China Veterinary Lyme Disease Vaccines Sales by Application (2021-2026) & (k doses) Table 143. China Veterinary Lyme Disease Vaccines Sales by Application (2027-2032) & (k doses) Table 144. China Veterinary Lyme Disease Vaccines Sales Price by Application (2021-2026) & (USD/dose) Table 145. China Veterinary Lyme Disease Vaccines Sales Price by Application (2027-2032) & (USD/dose) Table 146. Asia Veterinary Lyme Disease Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 147. Asia Veterinary Lyme Disease Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 148. Asia Veterinary Lyme Disease Vaccines Sales by Type (2021-2026) & (k doses) Table 149. Asia Veterinary Lyme Disease Vaccines Sales by Type (2027-2032) & (k doses) Table 150. Asia Veterinary Lyme Disease Vaccines Sales Price by Type (2021-2026) & (USD/dose) Table 151. Asia Veterinary Lyme Disease Vaccines Sales Price by Type (2027-2032) & (USD/dose) Table 152. Asia Veterinary Lyme Disease Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 153. Asia Veterinary Lyme Disease Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 154. Asia Veterinary Lyme Disease Vaccines Sales by Application (2021-2026) & (k doses) Table 155. Asia Veterinary Lyme Disease Vaccines Sales by Application (2027-2032) & (k doses) Table 156. Asia Veterinary Lyme Disease Vaccines Sales Price by Application (2021-2026) & (USD/dose) Table 157. Asia Veterinary Lyme Disease Vaccines Sales Price by Application (2027-2032) & (USD/dose) Table 158. Asia Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 159. Asia Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 160. Asia Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 161. Asia Veterinary Lyme Disease Vaccines Sales by Country (2021 VS 2025 VS 2032) & (k doses) Table 162. Asia Veterinary Lyme Disease Vaccines Sales by Country (2021-2026) & (k doses) Table 163. Asia Veterinary Lyme Disease Vaccines Sales by Country (2027-2032) & (k doses) Table 164. Asia Veterinary Lyme Disease Vaccines Sales Price by Country (2021-2026) & (USD/dose) Table 165. Asia Veterinary Lyme Disease Vaccines Sales Price by Country (2027-2032) & (USD/dose) Table 166. Japan Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 167. South Korea Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 168. India Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 169. Australia Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 170. Taiwan Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 171. Southeast Asia Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 172. SAMEA Veterinary Lyme Disease Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 173. SAMEA Veterinary Lyme Disease Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 174. SAMEA Veterinary Lyme Disease Vaccines Sales by Type (2021-2026) & (k doses) Table 175. SAMEA Veterinary Lyme Disease Vaccines Sales by Type (2027-2032) & (k doses) Table 176. SAMEA Veterinary Lyme Disease Vaccines Sales Price by Type (2021-2026) & (USD/dose) Table 177. SAMEA Veterinary Lyme Disease Vaccines Sales Price by Type (2027-2032) & (USD/dose) Table 178. SAMEA Veterinary Lyme Disease Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 179. SAMEA Veterinary Lyme Disease Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 180. SAMEA Veterinary Lyme Disease Vaccines Sales by Application (2021-2026) & (k doses) Table 181. SAMEA Veterinary Lyme Disease Vaccines Sales by Application (2027-2032) & (k doses) Table 182. SAMEA Veterinary Lyme Disease Vaccines Sales Price by Application (2021-2026) & (USD/dose) Table 183. SAMEA Veterinary Lyme Disease Vaccines Sales Price by Application (2027-2032) & (USD/dose) Table 184. SAMEA Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 185. SAMEA Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 186. SAMEA Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 187. SAMEA Veterinary Lyme Disease Vaccines Sales by Country (2021 VS 2025 VS 2032) & (k doses) Table 188. SAMEA Veterinary Lyme Disease Vaccines Sales by Country (2021-2026) & (k doses) Table 189. SAMEA Veterinary Lyme Disease Vaccines Sales by Country (2027-2032) & (k doses) Table 190. SAMEA Veterinary Lyme Disease Vaccines Sales Price by Country (2021-2026) & (USD/dose) Table 191. SAMEA Veterinary Lyme Disease Vaccines Sales Price by Country (2027-2032) & (USD/dose) Table 192. Brazil Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 193. Argentina Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 194. Chile Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 195. Colombia Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 196. Peru Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 197. Saudi Arabia Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 198. Israel Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 199. UAE Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 200. Turkey Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 201. Iran Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 202. Egypt Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Table 203. Key Raw Materials Table 204. Raw Materials Key Suppliers Table 205. Veterinary Lyme Disease Vaccines Distributors List Table 206. Veterinary Lyme Disease Vaccines Customers List Table 207. Research Programs/Design for This Report Table 208. Authors List of This Report Table 209. Secondary Sources Table 210. Primary Sources List of Figures Figure 1. Veterinary Lyme Disease Vaccines Image Figure 2. Global Veterinary Lyme Disease Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Veterinary Lyme Disease Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 4. Recombinant Subunit Vaccines Image Figure 5. Bacterin Vaccines Image Figure 6. Global Veterinary Lyme Disease Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Veterinary Lyme Disease Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 8. Canine Image Figure 9. Feline Image Figure 10. Global Veterinary Lyme Disease Vaccines Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Veterinary Lyme Disease Vaccines Revenue (2021-2032) & (US$ Million) Figure 12. Global Veterinary Lyme Disease Vaccines Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 13. Global Veterinary Lyme Disease Vaccines Revenue Market Share by Region: 2025 Versus 2032 Figure 14. Global Veterinary Lyme Disease Vaccines Revenue Market Share by Region (2021-2032) Figure 15. Global Veterinary Lyme Disease Vaccines Sales (2021-2032) & (k doses) Figure 16. Global Veterinary Lyme Disease Vaccines Sales by Region: 2021 VS 2025 VS 2032 (k doses) Figure 17. Global Veterinary Lyme Disease Vaccines Sales Market Share by Region (2021-2032) Figure 18. US & Canada & Mexico Veterinary Lyme Disease Vaccines Sales YoY (2021-2032) & (k doses) Figure 19. Europe Veterinary Lyme Disease Vaccines Sales YoY (2021-2032) & (k doses) Figure 20. China Veterinary Lyme Disease Vaccines Sales YoY (2021-2032) & (k doses) Figure 21. Asia (Excluding China) Veterinary Lyme Disease Vaccines Sales YoY (2021-2032) & (k doses) Figure 22. South America, Middle East and Africa Veterinary Lyme Disease Vaccines Sales YoY (2021-2032) & (k doses) Figure 23. Global Veterinary Lyme Disease Vaccines Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 24. Global Veterinary Lyme Disease Vaccines Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 25. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 26. Global Veterinary Lyme Disease Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Veterinary Lyme Disease Vaccines Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 28. Global Veterinary Lyme Disease Vaccines Revenue Market Share by Type (2021-2032) Figure 29. Global Veterinary Lyme Disease Vaccines Sales by Type (2021 VS 2025 VS 2032) & (k doses) Figure 30. Global Veterinary Lyme Disease Vaccines Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Veterinary Lyme Disease Vaccines Sales Market Share by Type (2021-2032) Figure 32. Global Veterinary Lyme Disease Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Veterinary Lyme Disease Vaccines Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 34. Global Veterinary Lyme Disease Vaccines Revenue Market Share by Application (2021-2032) Figure 35. Global Veterinary Lyme Disease Vaccines Sales by Application (2021 VS 2025 VS 2032) & (k doses) Figure 36. Global Veterinary Lyme Disease Vaccines Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Veterinary Lyme Disease Vaccines Sales Market Share by Application (2021-2032) Figure 38. North America Veterinary Lyme Disease Vaccines Revenue Share by Type (2021-2032) Figure 39. North America Veterinary Lyme Disease Vaccines Sales Share by Type (2021-2032) Figure 40. North America Veterinary Lyme Disease Vaccines Revenue Share by Application (2021-2032) Figure 41. North America Veterinary Lyme Disease Vaccines Sales Share by Application (2021-2032) Figure 42. North America Veterinary Lyme Disease Vaccines Revenue Share by Country (2021-2032) Figure 43. North America Veterinary Lyme Disease Vaccines Sales Share by Country (2021-2032) Figure 44. Europe Veterinary Lyme Disease Vaccines Revenue Share by Type (2021-2032) Figure 45. Europe Veterinary Lyme Disease Vaccines Sales Share by Type (2021-2032) Figure 46. Europe Veterinary Lyme Disease Vaccines Revenue Share by Application (2021-2032) Figure 47. Europe Veterinary Lyme Disease Vaccines Sales Share by Application (2021-2032) Figure 48. Europe Veterinary Lyme Disease Vaccines Revenue Share by Country (2021-2032) Figure 49. Europe Veterinary Lyme Disease Vaccines Sales Share by Country (2021-2032) Figure 50. China Veterinary Lyme Disease Vaccines Revenue Share by Type (2021-2032) Figure 51. China Veterinary Lyme Disease Vaccines Sales Share by Type (2021-2032) Figure 52. China Veterinary Lyme Disease Vaccines Revenue Share by Application (2021-2032) Figure 53. China Veterinary Lyme Disease Vaccines Sales Share by Application (2021-2032) Figure 54. Asia Veterinary Lyme Disease Vaccines Revenue Share by Type (2021-2032) Figure 55. Asia Veterinary Lyme Disease Vaccines Sales Share by Type (2021-2032) Figure 56. Asia Veterinary Lyme Disease Vaccines Revenue Share by Application (2021-2032) Figure 57. Asia Veterinary Lyme Disease Vaccines Sales Share by Application (2021-2032) Figure 58. Asia Veterinary Lyme Disease Vaccines Revenue Share by Country (2021-2032) Figure 59. Asia Veterinary Lyme Disease Vaccines Sales Share by Country (2021-2032) Figure 60. SAMEA Veterinary Lyme Disease Vaccines Revenue Share by Type (2021-2032) Figure 61. SAMEA Veterinary Lyme Disease Vaccines Sales Share by Type (2021-2032) Figure 62. SAMEA Veterinary Lyme Disease Vaccines Revenue Share by Application (2021-2032) Figure 63. SAMEA Veterinary Lyme Disease Vaccines Sales Share by Application (2021-2032) Figure 64. SAMEA Veterinary Lyme Disease Vaccines Revenue Share by Country (2021-2032) Figure 65. SAMEA Veterinary Lyme Disease Vaccines Sales Share by Country (2021-2032) Figure 66. Veterinary Lyme Disease Vaccines Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Veterinary Lyme Disease Vaccines Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant Subunit Vaccines
  • Bacterin Vaccines
Applications
  • Canine
  • Feline
Companies covered
  • Zoetis
  • Boehringer Ingelheim
  • Elanco
  • Merck Animal Health
  • Bioveta

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Veterinary Lyme Disease Vaccines Market by Type
  3. 1.2.1 Global Veterinary Lyme Disease Vaccines Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Recombinant Subunit Vaccines
  5. 1.2.3 Bacterin Vaccines
  6. 1.3 Veterinary Lyme Disease Vaccines Market by Application
  7. 1.3.1 Global Veterinary Lyme Disease Vaccines Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Canine
  9. 1.3.3 Feline
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Veterinary Lyme Disease Vaccines Market Dynamics
  1. 2.1 Veterinary Lyme Disease Vaccines Industry Trends
  2. 2.2 Veterinary Lyme Disease Vaccines Industry Drivers
  3. 2.3 Veterinary Lyme Disease Vaccines Industry Opportunities and Challenges
  4. 2.4 Veterinary Lyme Disease Vaccines Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Veterinary Lyme Disease Vaccines Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Veterinary Lyme Disease Vaccines Revenue by Region
  3. 3.2.1 Global Veterinary Lyme Disease Vaccines Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Veterinary Lyme Disease Vaccines Revenue by Region (2021-2026)
  5. 3.2.3 Global Veterinary Lyme Disease Vaccines Revenue by Region (2027-2032)
  6. 3.2.4 Global Veterinary Lyme Disease Vaccines Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Veterinary Lyme Disease Vaccines Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Veterinary Lyme Disease Vaccines Sales by Region
  9. 3.4.1 Global Veterinary Lyme Disease Vaccines Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Veterinary Lyme Disease Vaccines Sales by Region (2021-2026)
  11. 3.4.3 Global Veterinary Lyme Disease Vaccines Sales by Region (2027-2032)
  12. 3.4.4 Global Veterinary Lyme Disease Vaccines Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Veterinary Lyme Disease Vaccines Revenue by Manufacturers
  2. 4.1.1 Global Veterinary Lyme Disease Vaccines Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Veterinary Lyme Disease Vaccines Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Veterinary Lyme Disease Vaccines Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Veterinary Lyme Disease Vaccines Sales by Manufacturers
  6. 4.2.1 Global Veterinary Lyme Disease Vaccines Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Veterinary Lyme Disease Vaccines Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Veterinary Lyme Disease Vaccines Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Veterinary Lyme Disease Vaccines Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Veterinary Lyme Disease Vaccines Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Veterinary Lyme Disease Vaccines Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Veterinary Lyme Disease Vaccines Manufacturers, Product Type & Application
  13. 4.7 Global Veterinary Lyme Disease Vaccines Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Veterinary Lyme Disease Vaccines Market CR5 and HHI
  16. 4.8.2 2025 Veterinary Lyme Disease Vaccines Tier 1, Tier 2, and Tier 3
5 Veterinary Lyme Disease Vaccines Market by Type
  1. 5.1 Global Veterinary Lyme Disease Vaccines Revenue by Type
  2. 5.1.1 Global Veterinary Lyme Disease Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Veterinary Lyme Disease Vaccines Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Veterinary Lyme Disease Vaccines Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Veterinary Lyme Disease Vaccines Sales by Type
  6. 5.2.1 Global Veterinary Lyme Disease Vaccines Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Veterinary Lyme Disease Vaccines Sales by Type (2021-2032) & (k doses)
  8. 5.2.3 Global Veterinary Lyme Disease Vaccines Sales Market Share by Type (2021-2032)
  9. 5.3 Global Veterinary Lyme Disease Vaccines Price by Type
6 Veterinary Lyme Disease Vaccines Market by Application
  1. 6.1 Global Veterinary Lyme Disease Vaccines Revenue by Application
  2. 6.1.1 Global Veterinary Lyme Disease Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Veterinary Lyme Disease Vaccines Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Veterinary Lyme Disease Vaccines Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Veterinary Lyme Disease Vaccines Sales by Application
  6. 6.2.1 Global Veterinary Lyme Disease Vaccines Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Veterinary Lyme Disease Vaccines Sales by Application (2021-2032) & (k doses)
  8. 6.2.3 Global Veterinary Lyme Disease Vaccines Sales Market Share by Application (2021-2032)
  9. 6.3 Global Veterinary Lyme Disease Vaccines Price by Application
7 Company Profiles
  1. 7.1 Zoetis
  2. 7.1.1 Zoetis Company Information
  3. 7.1.2 Zoetis Business Overview
  4. 7.1.3 Zoetis Veterinary Lyme Disease Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Zoetis Veterinary Lyme Disease Vaccines Product Portfolio
  6. 7.1.5 Zoetis Recent Developments
  7. 7.2 Boehringer Ingelheim
  8. 7.2.1 Boehringer Ingelheim Company Information
  9. 7.2.2 Boehringer Ingelheim Business Overview
  10. 7.2.3 Boehringer Ingelheim Veterinary Lyme Disease Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Boehringer Ingelheim Veterinary Lyme Disease Vaccines Product Portfolio
  12. 7.2.5 Boehringer Ingelheim Recent Developments
  13. 7.3 Elanco
  14. 7.3.1 Elanco Company Information
  15. 7.3.2 Elanco Business Overview
  16. 7.3.3 Elanco Veterinary Lyme Disease Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Elanco Veterinary Lyme Disease Vaccines Product Portfolio
  18. 7.3.5 Elanco Recent Developments
  19. 7.4 Merck Animal Health
  20. 7.4.1 Merck Animal Health Company Information
  21. 7.4.2 Merck Animal Health Business Overview
  22. 7.4.3 Merck Animal Health Veterinary Lyme Disease Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Merck Animal Health Veterinary Lyme Disease Vaccines Product Portfolio
  24. 7.4.5 Merck Animal Health Recent Developments
  25. 7.5 Bioveta
  26. 7.5.1 Bioveta Company Information
  27. 7.5.2 Bioveta Business Overview
  28. 7.5.3 Bioveta Veterinary Lyme Disease Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Bioveta Veterinary Lyme Disease Vaccines Product Portfolio
  30. 7.5.5 Bioveta Recent Developments
8 North America
  1. 8.1 North America Veterinary Lyme Disease Vaccines Market Size by Type
  2. 8.1.1 North America Veterinary Lyme Disease Vaccines Revenue by Type (2021-2032)
  3. 8.1.2 North America Veterinary Lyme Disease Vaccines Sales by Type (2021-2032)
  4. 8.1.3 North America Veterinary Lyme Disease Vaccines Price by Type (2021-2032)
  5. 8.2 North America Veterinary Lyme Disease Vaccines Market Size by Application
  6. 8.2.1 North America Veterinary Lyme Disease Vaccines Revenue by Application (2021-2032)
  7. 8.2.2 North America Veterinary Lyme Disease Vaccines Sales by Application (2021-2032)
  8. 8.2.3 North America Veterinary Lyme Disease Vaccines Price by Application (2021-2032)
  9. 8.3 North America Veterinary Lyme Disease Vaccines Market Size by Country
  10. 8.3.1 North America Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Veterinary Lyme Disease Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Veterinary Lyme Disease Vaccines Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Veterinary Lyme Disease Vaccines Market Size by Type
  2. 9.1.1 Europe Veterinary Lyme Disease Vaccines Revenue by Type (2021-2032)
  3. 9.1.2 Europe Veterinary Lyme Disease Vaccines Sales by Type (2021-2032)
  4. 9.1.3 Europe Veterinary Lyme Disease Vaccines Price by Type (2021-2032)
  5. 9.2 Europe Veterinary Lyme Disease Vaccines Market Size by Application
  6. 9.2.1 Europe Veterinary Lyme Disease Vaccines Revenue by Application (2021-2032)
  7. 9.2.2 Europe Veterinary Lyme Disease Vaccines Sales by Application (2021-2032)
  8. 9.2.3 Europe Veterinary Lyme Disease Vaccines Price by Application (2021-2032)
  9. 9.3 Europe Veterinary Lyme Disease Vaccines Market Size by Country
  10. 9.3.1 Europe Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Veterinary Lyme Disease Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Veterinary Lyme Disease Vaccines Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Veterinary Lyme Disease Vaccines Market Size by Type
  2. 10.1.1 China Veterinary Lyme Disease Vaccines Revenue by Type (2021-2032)
  3. 10.1.2 China Veterinary Lyme Disease Vaccines Sales by Type (2021-2032)
  4. 10.1.3 China Veterinary Lyme Disease Vaccines Price by Type (2021-2032)
  5. 10.2 China Veterinary Lyme Disease Vaccines Market Size by Application
  6. 10.2.1 China Veterinary Lyme Disease Vaccines Revenue by Application (2021-2032)
  7. 10.2.2 China Veterinary Lyme Disease Vaccines Sales by Application (2021-2032)
  8. 10.2.3 China Veterinary Lyme Disease Vaccines Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Veterinary Lyme Disease Vaccines Market Size by Type
  2. 11.1.1 Asia Veterinary Lyme Disease Vaccines Revenue by Type (2021-2032)
  3. 11.1.2 Asia Veterinary Lyme Disease Vaccines Sales by Type (2021-2032)
  4. 11.1.3 Asia Veterinary Lyme Disease Vaccines Price by Type (2021-2032)
  5. 11.2 Asia Veterinary Lyme Disease Vaccines Market Size by Application
  6. 11.2.1 Asia Veterinary Lyme Disease Vaccines Revenue by Application (2021-2032)
  7. 11.2.2 Asia Veterinary Lyme Disease Vaccines Sales by Application (2021-2032)
  8. 11.2.3 Asia Veterinary Lyme Disease Vaccines Price by Application (2021-2032)
  9. 11.3 Asia Veterinary Lyme Disease Vaccines Market Size by Country
  10. 11.3.1 Asia Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Veterinary Lyme Disease Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Veterinary Lyme Disease Vaccines Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Veterinary Lyme Disease Vaccines Market Size by Type
  2. 12.1.1 SAMEA Veterinary Lyme Disease Vaccines Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Veterinary Lyme Disease Vaccines Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Veterinary Lyme Disease Vaccines Price by Type (2021-2032)
  5. 12.2 SAMEA Veterinary Lyme Disease Vaccines Market Size by Application
  6. 12.2.1 SAMEA Veterinary Lyme Disease Vaccines Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Veterinary Lyme Disease Vaccines Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Veterinary Lyme Disease Vaccines Price by Application (2021-2032)
  9. 12.3 SAMEA Veterinary Lyme Disease Vaccines Market Size by Country
  10. 12.3.1 SAMEA Veterinary Lyme Disease Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Veterinary Lyme Disease Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Veterinary Lyme Disease Vaccines Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Veterinary Lyme Disease Vaccines Value Chain Analysis
  2. 13.1.1 Veterinary Lyme Disease Vaccines Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Veterinary Lyme Disease Vaccines Production Mode & Process
  6. 13.2 Veterinary Lyme Disease Vaccines Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Veterinary Lyme Disease Vaccines Distributors
  9. 13.2.3 Veterinary Lyme Disease Vaccines Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst